Chiome Bioscience Inc. FY2025 Q3 Earnings Report | IR Tracker

Chiome Bioscience Inc. FY2025 Q3 Earnings Report | IR Tracker

Financial Highlights

Net Sales: ¥369M
Operating Income: ¥-805M
Net Income: ¥-800M
EPS: ¥-11.79

Income Statement

Item	Current	Prior	YoY %
Net Sales	¥369M	¥422M	-12.6%
Cost of Sales	¥203M	-	-
Gross Profit	¥220M	-	-
SG&A Expenses	¥1.14B	-	-
Operating Income	¥-805M	¥-920M	+12.5%
Non-operating Income	¥22M	-	-
Non-operating Expenses	¥15M	-	-
Ordinary Income	¥-807M	¥-914M	+11.7%
Profit Before Tax	¥-913M	-	-
Income Tax Expense	¥3M	-	-
Net Income	¥-800M	¥-915M	+12.6%
Interest Expense	¥2M	-	-
Basic EPS	¥-11.79	¥-16.26	+27.5%
Dividend Per Share	¥0.00	¥0.00	-

Balance Sheet

Item	Current End	Prior End	Change
Current Assets	¥2.34B	-	-
Cash and Deposits	¥2.06B	-	-
Accounts Receivable	¥51M	-	-
Inventories	¥46M	-	-
Non-current Assets	¥131M	-	-

Profitability Ratios

Item	Value
Net Profit Margin	-216.8%
Gross Profit Margin	59.5%
Current Ratio	473.8%
Quick Ratio	464.4%
Debt-to-Equity Ratio	0.44x
Interest Coverage Ratio	-395.77x
Effective Tax Rate	-0.3%

Year-over-Year Comparison

Item	YoY Change
Net Sales YoY Change	-12.5%

Item	Value
Shares Outstanding (incl. Treasury)	68.05M shares
Treasury Stock	12K shares
Average Shares Outstanding	67.85M shares
Book Value Per Share	¥18.37

Dividend Information

Item	Amount
Q2 Dividend	¥0.00
Year-End Dividend	¥0.00

Segment Information

Segment	Revenue	Operating Income
DrugDiscoveryAndDevelopment	¥3M	¥-586M
DrugDiscoverySupport	¥370M	¥204M

Full Year Forecast

Item	Forecast
Dividend Per Share Forecast	¥0.00

Disclaimer

This data was automatically extracted from XBRL files. Please refer to the original disclosure documents for accuracy.